NCT04717765

Brief Summary

Introduction: There are several manifestations in the oral mucosa resulting from antineoplastic treatments by chemo (QT) or radiotherapy (RT). In this study we will collect the variables referring to oral mucositis (OM), radiodermatitis, osteonecrosis of the jaws (ONJ), hyposalivation and xerostomia, dysgeusia, pain, oral candidiasis (opportunistic infection), trismus, quality of life, oral hygiene. MO and hyposalivation, which are related to damage to the salivary glands, are the most common manifestations, and ONJ is the most difficult to treat. The dentist can play an important role in prevention and treatment these oral lesions, directly influencing the patient's quality of life and adherence to antineoplastic treatment. Objectives: The main objective is to evaluate the efficacy of the intervention, using LLL phototherapy and topical Vit E, in the OM. And the intervention through LLL phototherapy and LPRP in the ONJ. These interventions will be performed by dentists during antineoplastic medical treatment. Material and methods: clinical trial, randomized, with balanced randomization, single-blind (for the evaluator of the results) with 2 experimental arms and a control group, carried out in a single center. Group 1, intervention with LLL phototherapy, Group 2, intervention with application of topical Vit E and Group 3, mouthwash with 0.12% chlorhexidine (usual clinical information). 360 patients will participate in this study from the Units of Oncology Medicine, Radiotetaphic Medicine and Oral Medicine, Oral Surgery and Implantology at the University of Santiago de Compostela. The segment of the patients will be given, an initial visit and returns every day that hears the application of antineoplastic treatment for the group of LLL phototherapy, returns of 15 days, one month, three months, six months, nine months and one year. In these return visits, evaluations and questionnaires will be carried out regarding all the variables that we will collect. Predictable results: If the application of laser phototherapy or topical Vit E contributes to the cessation, reduction or improvement of the clinical evolution of the manifestation of oral lesions, these treatments could be immediately implemented in our Oral Medicine unit and could lay the foundations for its implementation in different public centers and private.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 22, 2021

Completed
19 days until next milestone

Study Start

First participant enrolled

February 10, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2023

Completed
Last Updated

November 29, 2023

Status Verified

November 1, 2023

Enrollment Period

2 years

First QC Date

January 11, 2021

Last Update Submit

November 27, 2023

Conditions

Keywords

DentistryHealth PromotionClinical trialOral MucositisRadiotherapyChemotherapyLasertherapyPhototherapyHyposalivationORNMRONJ

Outcome Measures

Primary Outcomes (8)

  • Prevention of oral mucositis with LLL phototherapy, evaluation using NCI-CTC mucositis scale of the "National Cancer Institute" - grade 1 to 5 - Chemotherapy

    The main objective is to evaluate whether LLL phototherapy acts on preventing oral mucositis in patients who will receive chemotherapy. The result will be determined by the percentage of patients who reduce the intensity of the manifestation and/or do not develop oral mucositis, for this we will use the NCI-CTC mucositis scale of the "National Cancer Institute". Grade refers to the severity. Grades 1 through 5 (the most severe). Will be compared to those who receive topical Vit. E or chlorhexidine mouthwash, in the prevention arms of the study.

    3 months

  • Prevention of osteonecrosis of the jaws with LLL phototherapy, evaluation using the MASCC scale - stage 1 to 3 - Chemotherapy

    The main objective is to assess whether LLL phototherapy works to prevent bone necrosis of the jaws in patients who need dental extractions and who will still receive chemotherapy. The result will be determined by the percentage of patients who do not develop bone necrosis after extraction and phototherapy, the " Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO/ASCO) Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw" will be used for classification of bone necroses. Stage refers to the severity. Stages 1 through 3 (the most severe). It will be compared with those who receive LPRF after extraction or only extraction, in the prevention arms of the study.

    6 months

  • Treatment of oral mucositis with LLL phototherapy, evaluation using NCI-CTC mucositis scale of the "National Cancer Institute" - grade 1 to 5 - Chemotherapy

    The main objective is to evaluate the efficacy of LLL phototherapy in the LLL phototherapy treating. The result will be determined by percentage of patients who develop oral mucositis after the first 10 days of treatment with chemotherapy, and who receive phototherapy, and have rapid regression of oral mucositis, for this we will use the NCI-CTC mucositis scale of the "National Cancer Institute". Grade refers to the severity. Grades 1 through 5 (the most severe). Will be compared with patients receiving topical Vit. E or chlorhexidine mouthwash.

    3 months

  • Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using the MASCC scale - stage 1 to 3 - Chemotherapy

    The main objective is to evaluate the efficacy of LLL phototherapy in the treatment of osteonecrosis of the jaws in patients with bone necrosis after receiving chemotherapy. The result will be determined by the percentage of patients who are cured of osteonecrosis after sequestromia and phototherapy, for this which we will use the " Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO/ASCO) Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw" will be used for classification of bone necroses. Stage refers to the severity. Stages 1 through 3 (the most severe). It will be compared to those who receive sequestromia and LPRF or just sequestromia.

    6 months

  • Prevention of oral mucositis with LLL phototherapy, evaluation using NCI-CTC mucositis scale of the "National Cancer Institute" - grade 1 to 5 - Radiotherapy

    The main objective is to evaluate whether LLL phototherapy acts on preventing oral mucositis in patients who will receive radiotherapy. The result will be determined by the percentage of patients who reduce the intensity of the manifestation and/or do not develop oral mucositis, for this we will use the NCI-CTC mucositis scale of the "National Cancer Institute". Grade refers to the severity. Grades 1 through 5 (the most severe). Will be compared with patients receiving topical Vit. E or chlorhexidine mouthwash.

    3 months

  • Prevention of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy

    The main objective is to assess whether LLL phototherapy works to prevent bone necrosis of the jaws in patients who need dental extractions and who will still receive radiotherapy. The result will be determined by the percentage of patients who do not develop bone necrosis after extraction and phototherapy, the Notani scale, will be used for classification of bone necroses. Grade refers to the severity. Grades 1 through 3 (the most severe).

    6 months

  • Treatment of oral mucositis with LLL phototherapy, evaluation using NCI-CTC mucositis scale of the "National Cancer Institute" - grade 1 to 5 - Radiotherapy

    The main objective is to evaluate the efficacy of LLL phototherapy in the LLL phototherapy treating. The result will be determined by percentage of patients who develop oral mucositis after the first 10 days of treatment with radiotherapy, and who receive phototherapy, and have rapid regression of oral mucositis, for this we will use the NCI-CTC mucositis scale of the "National Cancer Institute". Grade refers to the severity. Grades 1 through 5 (the most severe). Will be compared with patients receiving topical Vit. E or chlorhexidine mouthwash.

    3 months

  • Treatment of osteonecrosis of the jaws with LLL phototherapy, evaluation using Notani scale - grade 1 to 3 - Radiotherapy

    The main objective is to evaluate the efficacy of LLL phototherapy in the treatment of osteonecrosis of the jaws in patients with bone necrosis after receiving radiotherapy. The result will be determined by the percentage of patients who are cured of osteonecrosis after sequestromia and phototherapy, for which we will use the Notoni Scale. Grade refers to the severity. Grades 1 through 3 (the most severe).

    6 months

Secondary Outcomes (5)

  • Interference of oral mucositis with quality of life - QLQ-C30 test

    6 months

  • Interference of osteonecrosis of the jaws with quality of life - QLQ-C30 test

    12 months

  • Hyposalivation with global saliva test - Oral mucositis

    6 months

  • Xerostomia with s will be estimated by measurement. Xerostomia, with Xerostomia inventory - Oral mucositis

    6 months

  • Pain assessed by EVA - score 0 to 10 - all patients

    6 months

Study Arms (12)

Preventive in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy

EXPERIMENTAL

Application of LLL phototherapy from the first day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed. Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point.

Device: Preventive, LLL Phototherapy and topical Vit E

Preventive in oral mucositis caused by chemo or radiotherapy - Vit E

ACTIVE COMPARATOR

Topical Vit. E spray, from the first day to the last day, every day that the chemo or radiotherapy treatment is administered. Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day.

Device: Preventive, LLL Phototherapy and topical Vit E

Preventive in oral mucositis caused by chemo or radiotherapy - mouthwash

NO INTERVENTION

Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the first to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.

Curative in oral mucositis caused by chemo or radiotherapy - LLL Phototherapy

EXPERIMENTAL

Application of LLL phototherapy from the tenth day until the last day, on all days that the chemo or radiotherapy treatment is administered. If the patient still shows evidence of mucositis at the end of the treatment, additional applications can be performed. Application: in wavelength 660 nm (red), there will be 78 intra oral points, with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point.

Device: Curative, LLL Phototherapy and topical Vit E

Curative in oral mucositis caused by chemo or radiotherapy - mucositis Vit E

ACTIVE COMPARATOR

Topical Vit. E spray, application from the tenth day, and until the last day, every day that the chemo or radiotherapy treatment is administered. Application: on the first day the professional will demonstrate the application on intra-oral mucous points. On the other days the patient will do self application, twice a day.

Device: Curative, LLL Phototherapy and topical Vit E

Curative in oral mucositis caused by chemo or radiotherapy- mouthwash

NO INTERVENTION

Oral hygiene control and mouthwash with chlorhexidine 0.12%, from the tenth to the last day of administration of the chemo or radiotherapy treatment. On the first day the professional will demonstrate the care. On the other days the care will be taken by the patient himself, for at least three times a day.

Preventive osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + extraction

EXPERIMENTAL

For patients who need dental extraction for the adequacy of the oral cavity. Application of LLL phototherapy on the day the dental extraction is performed and every 72hr, totaling 5 applications. It must be done at least 3 months before the beginning of the chemo or radiotherapy treatment. Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of the root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point.

Device: Preventive, LLL Phototherapy and LPRF

Preventive osteonecrosis resulting from chemo or radiotherapy - LPRF+ extraction

ACTIVE COMPARATOR

For patients who need dental extraction for the adequacy of the oral cavity. LPRF placement on the day the tooth extraction is performed. The procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment. After the LPRF has been placed, the suture should be done in a way that facilitates healing for primary intention.

Device: Preventive, LLL Phototherapy and LPRF

Preventive osteonecrosis resulting from chemo or radiotherapy - extraction only

NO INTERVENTION

For patients who need dental extraction for the adequacy of the oral cavity, the procedure must be performed at least 3 months before the start of chemo or radiotherapy treatment. The suture should be done in a way that facilitates healing for primary intention.

Curative osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + sequestrectomy

EXPERIMENTAL

Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and application of LLL phototherapy on the day of surgery and every 72hr, totaling 5 applications. The suture should be done in a way to facilitate healing for primary intention. Application: in wavelength 660 nm (red), alveolar ridge, 1 point per cm², with a time of 10 seconds per point, at a power of 100 mw, totaling a power of 1J per point. In wavelength 808 nm (infrared), buccal and lingual/palatal board 2 points in the length of what would be the dental root, with a time of 20 seconds per point, at a power of 100 mw, totaling a power of 2J per point.

Device: Curative, LLL Phototherapy and LPRF

Curative osteonecrosis resulting from chemo or radiotherapy - LPRF + sequestrectomy

ACTIVE COMPARATOR

Patients who have been diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy, removal of necrotic tissue and placement of the LPRF on the day of surgery will be performed. After the LPRF is placed, the suture should be done in a way that facilitates healing for primary intention.

Device: Curative, LLL Phototherapy and LPRF

Curative osteonecrosis resulting from chemo or radiotherapy - sequestrectomy only

NO INTERVENTION

Patients who were diagnosed with bone necrosis after treatment with chemo or radiotherapy, clinical confirmation and radiography. Bone sequestrectomy and removal of necrotic tissue will be performed. The suture should be done in a way that facilitates healing for primary intention.

Interventions

Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.

Preventive in oral mucositis caused by chemo or radiotherapy - LLL PhototherapyPreventive in oral mucositis caused by chemo or radiotherapy - Vit E

Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.

Curative in oral mucositis caused by chemo or radiotherapy - LLL PhototherapyCurative in oral mucositis caused by chemo or radiotherapy - mucositis Vit E

Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.

Preventive osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + extractionPreventive osteonecrosis resulting from chemo or radiotherapy - LPRF+ extraction

Interventions will be carried out for patients who have already passed or will undergo anti-neoplastic chemotherapy or radiation therapy.

Curative osteonecrosis resulting from chemo or radiotherapy - LLL Phototherapy + sequestrectomyCurative osteonecrosis resulting from chemo or radiotherapy - LPRF + sequestrectomy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with head and neck or breast cancer who will undergo chemotherapy or radiotherapy.

You may not qualify if:

  • Participants who do not sign the informed consent.
  • Patients who have been or will be treated by chemo and radiotherapy together.
  • Patients in treatment of a cancer recurrence.
  • Patients reporting diabetes or sjogren's syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Clinico Universitário

Santiago de Compostela, LA Coruña, 15702, Spain

Location

MeSH Terms

Conditions

StomatitisOsteoradionecrosisBisphosphonate-Associated Osteonecrosis of the JawXerostomiaHead and Neck NeoplasmsMouth Neoplasms

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesRadiation InjuriesWounds and InjuriesOsteonecrosisBone DiseasesMusculoskeletal DiseasesJaw DiseasesNecrosisPathologic ProcessesPathological Conditions, Signs and SymptomsSalivary Gland DiseasesNeoplasms by SiteNeoplasms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 11, 2021

First Posted

January 22, 2021

Study Start

February 10, 2021

Primary Completion

February 28, 2023

Study Completion

August 31, 2023

Last Updated

November 29, 2023

Record last verified: 2023-11

Locations